NASDAQ:PTIX Protagenic Therapeutics (PTIX) Stock Price, News & Analysis $0.22 +0.00 (+1.49%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.22 0.00 (-0.46%) As of 04/25/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Protagenic Therapeutics Stock (NASDAQ:PTIX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PTIX alerts:Sign Up Key Stats Today's Range$0.20▼$0.2350-Day Range$0.20▼$0.4252-Week Range$0.18▼$1.87Volume174,090 shsAverage Volume1.48 million shsMarket Capitalization$1.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewProtagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.Read More… Protagenic Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks16th Percentile Overall ScorePTIX MarketRank™: Protagenic Therapeutics scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Protagenic Therapeutics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Protagenic Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Protagenic Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProtagenic Therapeutics has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Protagenic Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.08% of the float of Protagenic Therapeutics has been sold short.Short Interest Ratio / Days to CoverProtagenic Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Protagenic Therapeutics has recently decreased by 62.09%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProtagenic Therapeutics does not currently pay a dividend.Dividend GrowthProtagenic Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.08% of the float of Protagenic Therapeutics has been sold short.Short Interest Ratio / Days to CoverProtagenic Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Protagenic Therapeutics has recently decreased by 62.09%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Protagenic Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for PTIX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Protagenic Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders35.00% of the stock of Protagenic Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.97% of the stock of Protagenic Therapeutics is held by institutions.Read more about Protagenic Therapeutics' insider trading history. Receive PTIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagenic Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PTIX Stock News HeadlinesProtagenic Therapeutics adjusts stock option pricesFebruary 26, 2025 | uk.investing.comPTIX stock touches 52-week low at $0.25 amid sharp annual declineFebruary 11, 2025 | msn.comM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big change. Make America Wealthy Again (M.A.W.A).April 26, 2025 | Paradigm Press (Ad)Avalon Holdings (AMEX:AWX) Stock Quotes, Forecast and News SummaryJanuary 31, 2025 | benzinga.comPerformance Tech stock hits 52-week low at $0.4January 30, 2025 | msn.comProtagenic Therapeutics faces Nasdaq delisting over equity deficitDecember 5, 2024 | investing.comProtagenic Therapeutics, Inc.: Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 MillionNovember 5, 2024 | finanznachrichten.deProtagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric DisordersMay 22, 2024 | finance.yahoo.comSee More Headlines PTIX Stock Analysis - Frequently Asked Questions How have PTIX shares performed this year? Protagenic Therapeutics' stock was trading at $0.49 at the beginning of the year. Since then, PTIX stock has decreased by 55.5% and is now trading at $0.2180. View the best growth stocks for 2025 here. How were Protagenic Therapeutics' earnings last quarter? Protagenic Therapeutics, Inc. (NASDAQ:PTIX) released its quarterly earnings data on Monday, March, 31st. The company reported ($0.24) earnings per share (EPS) for the quarter. How do I buy shares of Protagenic Therapeutics? Shares of PTIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Protagenic Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Protagenic Therapeutics investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), NVIDIA (NVDA), Cytokinetics (CYTK), Processa Pharmaceuticals (PCSA), Acasti Pharma (ACST) and Akero Therapeutics (AKRO). Company Calendar Last Earnings3/31/2025Today4/26/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PTIX CIK1022899 Webwww.protagenic.com Phone212-994-8200Fax603-761-6223Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,000,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-308.97% Return on Assets-228.73% Debt Debt-to-Equity RatioN/A Current Ratio1.80 Quick Ratio1.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.83 per share Price / Book0.26Miscellaneous Outstanding Shares7,526,000Free Float4,707,000Market Cap$1.64 million OptionableNot Optionable Beta0.34 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:PTIX) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagenic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagenic Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.